CHICAGO--(BUSINESS WIRE)--Fitch Ratings has assigned an 'A+(EXP)' rating to Pfizer's senior unsecured notes offering. The net proceeds of the issuance will be used to fund the purchase of the company's 6.2% notes due March 15, 2019.
The ratings apply to roughly $42.3 billion of debt outstanding at July 3, 2016. A full list of ratings follows at the end of this release.
KEY RATING DRIVERS
Little Leverage Flexibility: Despite Fitch's expectation that Pfizer will continue to generate stable operating performance and significant free cash flow (FCF), leverage remains strained, stemming from acquisitions and share repurchases during the past two years. The company's net cash outlays for acquisitions and share repurchases were roughly $30.5 billion during the period (excluding the subsequent $14 billion acquisition of Medivation), while FCF was $7 billion. As a result, Pfizer currently has little-to-no flexibility to increase leverage further within the 'A+' rating category.
Strategic Uncertainty Removed: Pfizer will retain its Global Established Pharmaceuticals (GEP) business for the time being. Fitch would view a divestiture as strategically positive for Pfizer, as it would narrow the company's focus on its higher margin, innovative portfolio. However, the company's business model would be more reliant on its innovative drug discovery efforts. Regardless, the decision removes the uncertainty regarding whether it would decrease debt subsequent to the spin.
Manageable Patent Expiries: The company's intermediate-term patent cliff is manageable. Over the next three years, roughly 18% of standalone Pfizer's drug portfolio is at risk of losing market exclusivity, including two of its five best-selling medicines - Lyrica (approximately 10% of total firm sales) and Enbrel (approximately 7%). The base patent for Enbrel expired internationally beginning in 2015. Pfizer does not have rights to Enbrel in the U.S. and Canada, but does receive modest royalty income from Amgen for sales in those regions. Lyrica's U.S. patent expires in late 2018.
Fitch does not expect that Enbrel will face as serious a competitive threat from generic alternatives as with traditional small molecules such as Lyrica. Enbrel is a biologic, and a generic biologic that is automatically interchangeable with Enbrel will not likely emerge. Therefore, Fitch expects competitive challengers will require significant research and marketing investments, making steep price discounts and drastic market share gains by competitors less likely.
Pipeline Successes: Helping to mitigate the anticipated revenue challenges from patent expiries, Pfizer has added new revenue sources over the past two years, including Ibrance/palbociclib (breast cancer), Trumenba (Neisseria meningitis vaccine), (Duavee (vasomotor symptoms of menopause), Adult Prevnar 13 (pneumococcal vaccine expanded use), Xeljanz (arthritis) and Bosulif (cancer).
The company is making progress with late-stage pipeline candidates, such as tafamidis (polyneuropathy), dacomitinib (lung cancer), inotuzumab (leukemia), tanezumab (pain) and avelumab (various cancers). Pfizer is conducting clinical trials that could expand the market of its marketed products by gaining approvals for their broader clinical use. Pfizer is also pursuing external pipeline projects through collaborations and acquisitions, such as its recent acquisition of Medivation.
Fitch's key assumptions for Pfizer include:
--Mid-single-digit organic revenue growth during 2016-2017 supported by newer product sales and manageable patent expiries;
--Incrementally improving margins driven by new product sales mix and the achievement of $800 million in Hospira acquisition related cost savings;
--Annual FCF (cash flow from operations minus capital expenditures minus dividends) of $6 billion to $7 billion during 2016-2017;
--Leverage to decline to below 1.7x by 2017 through increased operational EBITDA or a combination of debt reduction and increased EBITDA.
Positive: While Fitch does not anticipate a positive rating action in the near term, future developments that may individually or collectively, lead to such an action include:
--If Pfizer maintains gross debt leverage in the range of 1.0x to 1.3x;
--If the company sustains strong operational performance through the current patent cliff period, including relatively stable-to-positive trends in revenues, margins and FCF.
Negative: Future developments that may individually or collectively, lead to a negative rating action include:
--If Pfizer does not return to a sustainable gross debt leverage of 1.7x or lower. This could stem from marketplace pressures, adverse actions from regulatory bodies, unfavorable clinical developments or an aggressive capital deployment strategy;
--If Pfizer pursues transactions (another large acquisition and/or significant share repurchases) that place pressure on gross leverage without the expectation of deleveraging in a timely manner.
Adequate Liquidity: Fitch looks for Pfizer to maintain solid liquidity through strong FCF generation and ample access to the credit markets. FCF for the latest 12 months (LTM) ending July 3, 2016 was $6.2 billion. At the end of the period, Pfizer had approximately $20.9 billion in cash/short-term investments and full availability on its $7 billion revolver, maturing in November 2020.
Fitch views Pfizer's debt maturity schedule as manageable and expects the company to refinance the vast majority of its upcoming maturities with additional borrowings. Pfizer has approximately $3.7 billion of long-term debt maturing in 2016, $4.3 billion in 2017 and $2.3 billion in 2018.
FULL LIST OF RATINGS
Fitch currently rates Pfizer as follows:
--Short-Term Issuer Default Rating (IDR) 'F1';
--Commercial paper 'F1';
--Long-Term IDR 'A+';
--Credit facility 'A+';
--Senior unsecured notes 'A+';
The Rating Outlook is Stable.
--Long-Term IDR 'A+';
--Senior unsecured notes 'A+'.
--Long-Term IDR 'A+';
--Senior unsecured notes 'A+'.
Date of Relevant Committee: April 6, 2016
Summary of Financial Statement Adjustments - Financial statement adjustments that depart materially from those contained in the published financial statements of the relevant rated entity or obligor are disclosed below:
--Historical and projected EBITDA are adjusted to add back non-cash stock based compensation.
Additional information is available on www.fitchratings.com
Corporate Rating Methodology - Including Short-Term Ratings and Parent and Subsidiary Linkage - Effective from 17 August 2015 to 27 September 2016 (pub. 17 Aug 2015)
Copyright © 2016 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third- party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch's ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed.
The information in this report is provided "as is" without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers.
For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001